Picture EBD Group Connector Personal Networking in Life Sciences 650x80
Document › Details

AMETEK, Inc.. (11/1/16). "Press Release: AMETEK Completes Private Placement Offering. Note Offering of 500 Million Euros and 225 Million British Pounds". Berwyn, PA.

Organisation Organisation AMETEK Inc. (NYSE: AME)
  Group AMETEK (Group)
Products Product analytical instrument
  Product 2 banking

AMETEK, Inc. (NYSE: AME) announced that it has entered into an agreement to sell the equivalent of approximately $825 million in Senior Notes in a private placement with institutional investors at a weighted average interest rate of 1.82% and a weighted average maturity of 11.5 years. Proceeds from the offering will be used to repay existing debt and to provide capital to support our growth strategies.

There are two funding dates for the Senior Notes. The first funding occurred on October 31, 2016 for €500 million, consisting of €300 million in aggregate principal amount of 1.34% Senior Notes due October 2026 and €200 million in aggregate principal amount of 1.53% Senior Notes due October 2028. The second funding date will be November 23, 2016 for £225 million, consisting of £150 million in aggregate principal amount of 2.59% Senior Notes due November 2028 and £75 million in aggregate principal amount of 2.70% Senior Notes due November 2031.

The Senior Notes have not been registered, and will not be registered, under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act of 1933.

Corporate Profile

AMETEK is a leading global manufacturer of electronic instruments and electro-mechanical devices with annual sales of approximately $4.0 billion. AMETEK's Corporate Growth Plan is based on Four Key Strategies: Operational Excellence, Strategic Acquisitions, Global & Market Expansion and New Products. AMETEK's objective is double-digit percentage growth in earnings per share over the business cycle and a superior return on total capital. The common stock of AMETEK is a component of the S&P 500 Index.

Forward-looking Information

Statements in this news release relating to future events, such as AMETEK’s expected business and financial performance are "forward-looking statements." Forward-looking statements are subject to various factors and uncertainties that may cause actual results to differ significantly from expectations. These factors and uncertainties include AMETEK’s ability to consummate and successfully integrate future acquisitions; risks associated with international sales and operations; AMETEK’s ability to successfully develop new products, open new facilities or transfer product lines; the price and availability of raw materials; compliance with government regulations, including environmental regulations; changes in the competitive environment or the effects of competition in our markets; the ability to maintain adequate liquidity and financing sources; and general economic conditions affecting the industries we serve. A detailed discussion of these and other factors that may affect our future results is contained in AMETEK’s filings with the U.S. Securities and Exchange Commission, including its most recent reports on Form 10-K, 10-Q and 8-K. AMETEK disclaims any intention or obligation to update or revise any forward-looking statements.

Record changed: 2016-12-23


Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for AMETEK (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture BIO Deutschland German Corona Special 2021 Digital 650x80px

» top